Prestige Consumer Healthcare Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Prestige Consumer Healthcare closed the Breathe Right acquisition (June 2026, ~$200M annual revenue) and LaCorium Health acquisition (July 2026, ~$40M annual revenue) for a combined effective purchase of ~$900M net of tax benefits. Q1 FY27 organic revenue grew 3.2% to $265.7M; adjusted diluted EPS increased to $0.98 from $0.95 YoY. The company raised full-year FY27 revenue guidance from $1,100–$1,121M to $1,290–$1,315M and adjusted EPS guidance from $4.42–$4.51 to $4.55–$4.65, with ~$190M in anticipated acquisition revenue contributing nearly 20% to the revised guidance.
Why this rating
Two material acquisitions (~$190M revenue, ~6% of revised guidance base) deployed capital and added scale. Guidance raised modestly but organically soft (1–3% growth). Net debt ~$2B post-deal; leverage management and synergy realization are key risks vs. rewards.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.